PMC6594310_01
PET/CT image prior to immunotherapy.
CRIONM2019-2305315.001.jpg
PMC6594310_01_CRIONM2019-2305315.001.jpg
fig1
On first surveillance PET/CT, at 12 weeks postconcurrent chemoradiation treatment, she was found to have PET-avid hepatic and bone lesions (Figure 1).
Biopsy of metastatic lesion involving the portacaval lymph node.
CRIONM2019-2305315.002.jpg
PMC6594310_01_CRIONM2019-2305315.002.jpg
fig2
A CT-guided portacaval lymph node biopsy confirmed a metastatic disease (Figure 2).
PET/CT after 4 cycles of Pembrolizumab.
CRIONM2019-2305315.003.jpg
PMC6594310_01_CRIONM2019-2305315.003.jpg
fig3
Pembrolizumab monotherapy resulted in a near complete resolution of her hepatic metastasis and complete metabolic resolution of the left parotid mass, cervical adenopathy, and skeletal lesions on PET/CT following four cycles (Figure 3).